Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 40Lung Neoplasms 34Leukemia, Myeloid, Acute 34Breast Neoplasms 31Multiple Myeloma 25Carcinoma, Non-Small-Cell Lung 25Colorectal Neoplasms 23Prostatic Neoplasms 21Pancreatic Neoplasms 20Melanoma 17Carcinoma, Renal Cell 17Lymphoma 16Urinary Bladder Neoplasms 15Triple Negative Breast Neoplasms 15Ovarian Neoplasms 14Myelodysplastic Syndromes 14Burkitt Lymphoma 12Lymphoma, Large B-Cell, Diffuse 11Squamous Cell Carcinoma of Head and Neck 10Sarcoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Glioma 10Fallopian Tube Neoplasms 10Mouth Neoplasms 9Endometrial Neoplasms 9Carcinoma, Transitional Cell 9Carcinoma, Hepatocellular 9Carcinoma 9Oropharyngeal Neoplasms 8Laryngeal Neoplasms 8

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × Specimen Handling × 30 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡